Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features

Research output: Contribution to journalArticlepeer-review

Authors

  • A. L. Godfrey
  • P. J. Campbell
  • Cathy MacLean
  • G. Buck
  • J. Cook
  • J. Temple
  • B. S. Wilkins
  • J. Nangalia
  • J. Grinfeld
  • M. F. McMullin
  • C. Forsyth
  • J. J. Kiladjian
  • A. R. Green
  • C. N. Harrison

Colleges, School and Institutes

External organisations

  • Cambridge University Hospitals NHS Foundation Trust
  • Wellcome Trust Sanger Institute
  • University of Cambridge
  • University of Oxford
  • Guy's and St Thomas' NHS Foundation Trust
  • Queen's University Belfast
  • Gosford Hospital
  • Australasian Leukaemia and Lymphoma Group
  • Hôpital Saint-Louis
  • Wellcome Trust-MRC Cambridge Stem Cell Institute
  • Guy's and St Thomas' Hospitals NHS Foundation Trust

Abstract

Purpose Cytoreductive therapy is beneficial in patients with essential thrombocythemia (ET) at high risk of thrombosis. However, its value in those lacking high-risk features remains unknown. This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients with ET age 40 to 59 years and without high-risk factors or extreme thrombocytosis. Patients and Methods Patients were age 40 to 59 years and lacked a history of ischemia, thrombosis, embolism, hemorrhage, extreme thrombocytosis (platelet count ≥ 1,500 × 109/L), hypertension, or diabetes requiring therapy. In all, 382 patients were randomly assigned 1:1 to hydroxycarbamide plus aspirin or aspirin alone. The composite primary end point was time to arterial or venous thrombosis, serious hemorrhage, or death from vascular causes. Secondary end points were time to first arterial or venous thrombosis, first serious hemorrhage, death, incidence of transformation, and patient-reported quality of life. Results After a median follow-up of 73 months and a total follow-up of 2,373 patient-years, there was no significant difference between the arms in the likelihood of patients reaching the primary end point (hazard ratio, 0.98; 95% CI, 0.42 to 2.25; P = 1.0). The incidence of significant vascular events was low, at 0.93 per 100 patient-years (95% CI, 0.61 to 1.41). There were also no differences in overall survival; in the composite end point of transformation to myelofibrosis, acute myeloid leukemia, or myelodysplasia; in adverse events; or in patient-reported quality of life. Conclusion In patients with ET age 40 to 59 years and lacking high-risk factors for thrombosis or extreme thrombocytosis, preemptive addition of hydroxycarbamide to aspirin did not reduce vascular events, myelofibrotic transformation, or leukemic transformation. Patients age 40 to 59 years without other clinical indications for treatment (such as previous thrombosis or hemorrhage) who have a platelet count < 1,500 × 109/L should not receive cytoreductive therapy.

Details

Original languageEnglish
JournalJournal of Clinical Oncology
Early online date28 Aug 2018
Publication statusE-pub ahead of print - 28 Aug 2018